PROGRESS: Prevention of recurrent stroke

Hisatomi Arima, John Chalmers

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)


The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized placebo-controlled trial which clearly demonstrated that perindopril-based blood pressure (BP)-lowering treatment is one of the most effective and generalizable strategies for secondary prevention of stroke. Beneficial effects of BP lowering were observed on recurrent stroke, other cardiovascular events, disability, dependency, and cognitive function across a variety of subgroups defined by age, sex, geographical region, body mass index, diabetes, atrial fibrillation, chronic kidney disease, and baseline BP levels. Once patients with stroke have stabilized, all patients should receive BP-lowering therapy irrespective of their BP levels. On the basis of recommendations from current international guidelines, BP should be lowered to <140/90mmHg in all patients with cerebrovascular disease and to <130/80mmHg if therapy is well tolerated.

Original languageEnglish
Pages (from-to)693-702
Number of pages10
JournalJournal of Clinical Hypertension
Issue number9
Publication statusPublished - 2 Sept 2011
Externally publishedYes


Dive into the research topics of 'PROGRESS: Prevention of recurrent stroke'. Together they form a unique fingerprint.

Cite this